anlotinib + TQB2450 + nab-paclitaxel + cisplatin

This is a combination therapy consisting of four components: anlotinib (a multi-targeted tyrosine kinase inhibitor), TQB2450 (likely a PD-1 inhibitor), nab-paclitaxel (a nanoparticle albumin-bound formulation of paclitaxel), and cisplatin (a platinum-based chemotherapy agent). Anlotinib targets vascular endothelial growth factor receptor 2 and 3, fibroblast growth factor 1-4, platelet-derived growth factor receptor α and β, c-Kit and Ret, exhibiting anti-angiogenic and anti-tumor effects. Nab-paclitaxel is a taxane that disrupts microtubule function, while cisplatin causes DNA damage through cross-linking. This combination likely aims to simultaneously target multiple cancer pathways including angiogenesis, immune evasion, and cell division.